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Purpose of the Report: 
The usefulness of FDG-PET in pediatric Hodgkin lymphoma (p-HL) has been well 
demonstrated; however, pediatric non-Hodgkin lymphoma (p-NHL) has distinct 
characteristics from p-HL and adult NHL. We assessed roles of FDG-PET in p-NHL. 
Materials and Methods: 
Nineteen patients with p-NHL underwent 80 scans. Scans for staging (Group A, n=6) 
and response assessment (Group B, n=42) were compared with conventional imaging 
modalities (CIM). Scans within Group B for end-chemotherapy assessment (subgroup B+, 
n=11) and for post-therapeutic surveillance (Group C, n=32) were analyzed for diagnostic 
performance. 
Results: 
In Group A, PET and CIM demonstrated comparable. In Group B, PET diagnoses were 
concordant with CIM in 21 and discordant in 11. Of the discordant cases, PET suggested 
remnant lesions in 5 cases while CIM suggested in 6. PET modified therapeutic strategy in 
4 cases by detecting new extra-nodal lesions. In subgroup B+, sensitivity, specificity, and 
accuracy for predicting relapse were 50%, 71%, and 64%, respectively. In Group C, 
sensitivity, specificity, and accuracy were 100%, 87%, and 88%, respectively, but positive 




The role of FDG-PET in p-NHL may be limited, unlike with p-HL or adult NHL. 
Nevertheless, FDG-PET may serve complementarily in detecting unexpected lesions that 









Lymphoma is a common malignant disease in children, and has a different presentation 
from lymphoma in adults, especially in non-Hodgkin lymphoma (NHL). The majority of 
children with NHL have high-grade tumors. The presentation of pediatric NHL (p-NHL) is 
also different from that of pediatric Hodgkin lymphoma (p-HL). The tendency toward 
extra-nodal involvement is common in p-NHL but uncommon in p-HL.
1
 Overall survival 
rate is higher than 90% in p-HL and approximately 70% in p-NHL; however, prognosis is 




The utility of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) or 
PET/computed tomography (CT) using for children with lymphoma has yet to be 
sufficiently discussed, as compared to the extensive studies that have proven the 
considerable utility of FDG-PET in adult lymphoma.
3
 Recently, several articles have 
indicated the value of FDG-PET or PET/CT for pediatric lymphoma, and reported that 
disease staging and clinical management could be modified in 10–27% of cases.4-8 
However, in most published studies the number of patients with p-HL was larger than that 
of patients with p-NHL. Indeed, p-NHL represents approximately 60% of pediatric 
lymphomas with p-HL representing the remainder in the United States. Furthermore, p-HL 
is much rarer in Asian populations.
9
 Therefore, the patient population studied was not 
entirely representative of the overall incidence of p-HL and p-NHL. The European Network 
of Paediatric Hodgkin’s Lymphoma consists of over 100 treatment centers throughout the 
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European Union, and large-scale multicenter prospective studies about p-HL are 
underway.
10
 In contrast, there are still only a few studies that discuss the role of FDG-PET 
in p-NHL.
11
 Shankar et al. stated in their review article that unlike the validated or 
estimated utility in p-HL, the role of FDG-PET may be limited in p-NHL and its utility for 
response assessment has not been settled.
12
 Thus, it is considered preferable that the role of 
FDG-PET in p-NHL should be discussed separately from p-HL because of their different 
clinical manifestations and prognoses. Therefore, we evaluated the performance of FDG-
PET in p-NHL for initial staging, response assessment during chemotherapy, and 
surveillance for relapse. 
 
Materials and Methods 
 
Patients and study design 
Between February 2000 and June 2010, 19 patients (4 females and 15 males) under 20 
years of age (range, 2–18, median age at the time of initial study, 10) who had 
histologically-confirmed NHL underwent a total of 80 FDG-PET (or PET/CT) 
examinations at our institute. The histological tumor subtypes were Burkitt lymphoma in 6 
patients, DLBCL in 5 patients, lymphoblastic lymphoma in 5 patients, ALCL in 2 patients, 
and Natural Killer/T cell lymphoma in one patient. The stage of disease was evaluated 
according to the Murphy classification.
13
 Patients’ profiles including their treatment 
protocol and their outcome are given in Table 1. All studies involved daily clinical 
diagnostic checkups, and written informed consent was obtained from all patients along 
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with their parents as requested by our ethics committee. The examinations were divided 
into one of the following three groups, according to the purpose of the PET scan (Fig. 1).  
 
Group A: PET examinations for initial staging were assigned to this group. It included 
scans acquired after excision biopsy as long as they took place prior to the commencement 
of chemotherapy. This group comprised 6 studies in 6 patients. The contribution to staging 
was assessed through a comparison with conventional imaging modalities (CIM) such as 
ultrasound sonography, CT, or magnetic resonance imaging (MRI). 
 
Group B: PET examinations during or at the completion of chemotherapy were assigned 
to this group and included scans acquired after any number of cycles of chemotherapy. 
Examinations acquired during or after salvage therapy were also included. This group 
comprised 42 studies in 12 patients. Concordance or discordance in comparison with CIM 
and the influence on treatment plans were surveyed. 
We defined a further subgroup, termed “subgroup B+”, which consisted only of 
examinations for response assessment at the time of completion of remission-induction 
chemotherapy, excluding scans during or after salvage therapy. Subgroup B+ comprised 11 
studies in 11 patients. In this subgroup, PET scans were acquired 6–46 days (average 19 
days) after completion of the scheduled chemotherapy regimen. Diagnostic performance at 
predicting relapse was estimated by calculating the sensitivity, specificity, positive 




Group C: This group included PET scans acquired for follow-up surveillance for 
recurrence after the achievement of complete remission and comprised 32 studies in 13 
patients. Diagnostic performance at detecting relapse was estimated. 
 
PET or PET/CT scanning 
The administered dose of FDG was determined in accordance with the revised European 
Association of Nuclear Medicine (EANM) pediatric dosage card after 2008.
14
 Earlier than 
the publication date administered activity concentrations were approximately 6 MBq/kg 
(0.16mCi/kg) for 2-dimensional (2D) mode acquisition and approximately 3 MBq/kg 
(0.08mCi/kg) for 3-dimensional (3D) mode acquisitions. Patients received intravenous 
administration of FDG after fasting for at least 4 hours, and whole-body PET images were 
acquired approximately 50 minutes later. 
Eighteen studies were performed using a combined 3D PET/CT scanner (Discovery ST 
Elite, GE Healthcare, Waukesha, WI), which integrates a bismuth germinate crystal PET 
system with a 16-slice multi-detector-row CT. Fifty-seven studies were performed using a 
2D PET scanner (Advance, GE Healthcare, Waukesha, WI), and the remaining 5 studies 
were performed using a 3D PET scanner (C-PET plus, ADAC, Philadelphia, PA). The 
extent of image acquisition was usually from skull to upper thighs. Entire legs and arms 
were included when involvement was suspected. The need for sedation during acquisition 





Standard of reference 
In the staging of lymphoma, clinical staging as a standard of reference was determined 
using all imaging modalities, tissue diagnosis, bone marrow biopsy, and cerebrospinal fluid 
cytology.  
For the chemotherapy response assessment and recurrence surveillance cases, all patients 
underwent
 
regular follow-up for at least 6 months with the exception of those who died of 
progressive disease within their follow-up period. The diagnoses of relapse after remission 
required confirmation by biopsy and histological
 
examination. However, when tumors did 
not show remission in spite of chemotherapy, tumor enlargement at subsequent images was 
regarded as an evidence of tumor relapse. When there were no abnormal image findings 
suggesting relapse during their follow-up period, they were considered to be no evidence of 
recurrent disease. Spontaneous disappearance of FDG uptake at subsequent scan was also 
considered benign reactive change. 
 
Interpretation and data analysis 
Interpretation of FDG-PET (or PET/CT) images was performed by consensus of at least 
two experienced nuclear medicine physicians, together with all available clinical 
information such as patients’ history, physical examination, chemotherapy protocol, and 
prior imaging data. Interpretation criteria were determined according to those provided in 
the consensus guidelines of the Imaging Subcommittee of the International Harmonization 
Project in Lymphoma.
15
 In addition to the consensual criteria, we considered 
homogeneously increased thymus uptake with bi-lobed or inverted-“V” shape as an 
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exclusion of positive findings, since such uptake is ordinarily observed physiologically or 
as thymic rebound after chemotherapy in children and adolescents. Interpretation of CIM 
images was performed by experienced radiologists, together with all available clinical 





The results of initial staging are given in Table 2. FDG-PET did not contribute to up- or 
down-staging. As summarized in Table 3, PET staging results were comparable with those 
by CIM in all studies.  
In two cases, FDG-PET did not result in an accurate staging. Although these cases were 
both diagnosed as stage III by FDG-PET and CIM, the final determined stage was IV as a 
result of positive bone marrow biopsy in one case and positive cerebrospinal fluid cytology 
in the other. In the case of bone marrow involvement (No. 5), FDG-PET showed diffuse 
moderate uptake in bone marrow, which was read as equivocal since it was difficult to 
distinguish tumor involvement from physiological hypermetabolic bone marrow. 
 
Group B 
The judgments about the achievement of remission were concordant with the findings 
obtained by CIM in 21 studies and discordant in 11 studies. In the remaining 10 studies, 
CIM findings were not available. Among the 21 concordant cases, both methods suspected 
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residual tumor in 11 cases, and suggested the achievement of remission in 10 cases. Among 
the 11 discordant studies, PET alone suspected residual tumor in 5 cases, and in the other 6 
cases, PET suggested the achievement of complete remission despite CIM results that 
showed a residual lesion (Fig. 2). It was difficult to determine which was predominant, but 
PET results contributed toward the alteration of treatment strategy in 4 cases, as listed in 
Table 4; PET detected additional bone involvement after chemotherapy that resulted in 
additional radiotherapy in 2 cases; PET showed recurrent bone and neural involvement that 
led to the withdrawal of standard therapy in the other 2 cases (Fig. 3). As shown in Table 4, 
two of these four cases were confirmed by biopsy or cytology. The remaining two cases 
(No. 3 each) were not, because she had already experienced recurrence repeatedly by that 
time. Tumor biopsies just after FDG-PET were not held except the abovementioned two 
additional lesions, which also made it difficult to consider which modality was predominant 
in this group. 
 
Subgroup B+ 
All 11 patients (No. 1-4, 8-14) also underwent CT or MRI as an end-of-chemotherapy 
assessment. FDG-PET showed abnormal uptake in four patients. Of these, one patient (No. 
2), whose PET finding indicated residual abdominal tumor, turned out to be positive by 
cerebrospinal fluid cytology and to have sciatic nerve involvement afterward. Another 
patient (No. 13) was found to have new bone involvement in her distal femur despite the 
disappearance of the primary abdominal tumor. Both of their diseases deteriorated 
thereafter. In the remaining two patients (No. 3, 12), FDG-PET showed residual uptake in 
11 
 
the primary tumor, however the tumor remained in remission until the end of their follow-
up period. For patient No. 12, who had a submandibular mass at the beginning of therapy, 
CT at the end of therapy showed a nonspecific lymph node, indicating that the CIM result 
was true-negative and the PET result was false-positive. 
 
FDG-PET showed no significant abnormal uptake in 7 patients. Of these, 5 patients (No. 
4, 8, 10, 11, 14) maintained remission without relapse. For patient No. 11, the CT scan 
showed a small residual tumor in the anterior mediastinum, suggesting that CIM showed a 
false-positive and PET showed a true-negative result. The remaining 2 patients relapsed 
afterward in spite of PET-negative results. In one patient (No. 9), who had lymphoma of 
thymus, FDG-PET at the end of chemotherapy showed only physiological uptake in the 
thymus, but focal intense uptake superimposed on physiological thymic uptake was 
observed 8 months later and the lesion was resected and proven to be in relapse (Fig.4). 
This patient was also found to have bone marrow involvement, and died as a consequence 
of the disease 17 months after the end-therapy assessment scan. In the other patient (No. 1), 
who had CNS involvement, tumor relapse was discovered in the testis 23 months after the 
scan. 
Thus, all the 4 cases that experienced relapse were confirmed by either histology or 
cytology in this subgroup. As summarized in Table 5, the sensitivity, specificity, PPV, 
NPV, and accuracy of FDG-PET for predicting relapse were 50%, 71%, 50%, 71%, and 
64%, respectively. CIM showed the same diagnostic performance, although the individual 





Among 32 studies performed, two (6.3%) indicated a relapse, both of which were 
confirmed histologically (No. 1, 9). PET identified the relapsed lesions in both cases, and 
there were no cases PET failed to detect a relapse. There were 4 false-positive results; the 
lesion was resected and proved to be lymphadenitis in one case, and no further 
accumulation was observed in subsequent studies of the remaining three cases. The other 
26 studies showed no abnormal uptake and to date no relapse has occurred. Moderate 
uptake was seen in an area corresponding to the thymus in several studies, but these 
incidences were regarded as physiological. Taken together, the sensitivity, specificity, PPV, 
NPV, and accuracy for relapse were 100%, 87%, 33%, 100%, and 88%, respectively, as 
summarized in Table 6.  
 
Discussion 
FDG-PET is acknowledged as being superior to other imaging modalities for the 
evaluation of malignant lymphoma. However, in the present study for p-NHL, the 
performance of FDG-PET was not as satisfactory as was expected based on prior 
experiences reported in the literature. 
In the present study, when used for initial staging, FDG-PET demonstrated no 
contribution to up- or down-staging compared with CIM. This may be because all patients 
except one with primary cutaneous lymphoma were in stage III or worse. In p-NHL, unlike 





 CIM are usually sufficient to detect such lesions. Depas et al. 
examined the initial staging of 19 pediatric patients (14 with p-HL and 5 with p-NHL) and 
observed discordance from conventional methods in three patients, none of whom had p-
NHL.
6
 Amthauer et al. studied the initial staging of six p-NHL patients, and reported the 
detection of additional nodal lesions in half of the patients, but resulting in the up-staging 
of only one patient.
11
 In addition, Murphy stage IV is described as the presence of bone 
marrow and/or CNS involvement.
13
 In the present study, FDG-PET did not result in correct 
up-staging of two cases because of undetected microscopic bone marrow and cerebrospinal 
involvement. Therefore, in p-NHL, our preliminary data suggest that the clinical role of 
FDG-PET for initial staging is limited; furthermore, it appears difficult to justify the 
omission of bone marrow biopsy and cerebrospinal fluid cytology even when PET shows 
negative results. Nevertheless, FDG-PET may be helpful for correct up-staging, for 
example, when massive extra-nodal bone marrow or CNS involvement is also present, as 
such cases were encountered in the present study for the scans acquired during 
chemotherapy. 
When FDG-PET was acquired during or at the end of chemotherapy, several results were 
obtained that were discordant from CIM, contrary to the findings with the initial staging 
group, in the present study. As for the cases where PET alone indicated negative, the 
discordance was thought to be influenced by the fact that FDG uptake mainly reflected 
biological activity dependent upon glucose metabolism while CIM simply represented 
morphological changes. These changes were not synchronous. Decreased FDG uptake often 
occurs soon after the initiation of chemotherapy and precedes tumor volume reduction. 
14 
 
Many studies have demonstrated that FDG-PET acquired in the early cycles of 
chemotherapy is superior to CT in predicting the effects of therapy.
16
 However, Terasawa 
et al. meta-analyzed the prognostic accuracy for interim response assessment and concluded 
that it was a reliable test for HL but remained unproven for NHL.
17
 Therefore, we caution 
against concluding that the disappearance of FDG uptake represents tumor cell 
disappearance and a desirable outcome in p-NHL. As for the cases where PET alone 
indicated positive, the discordance was presumed to be because of several reasons. First, 
tumor necrosis and inflammation after chemotherapy may be causes of “false” positive 
uptake, although no case was confirmed histopathologically. Riad et al. noted that such 
phenomenon frequently occurred in Burkitt lymphoma, based upon their surgically 
validated experiences.
18
 Second, unexpected relapses were identified as a new “true” 
positive uptake in several cases. It is important to note that more than 90% of p-NHL cases 
have high-grade tumor and aggressive behavior.
2
 Patients with chemotherapy-resistant 
lymphoma tend towards rapid progressive relapse.
19
 FDG-PET would be an effective 
modality for detecting such lesions. We presume that the discordant positive uptake arising 
from these reasons may be one of the distinct FDG-PET imaging characteristics of p-NHL 
when compared to p-HL.  
The results of FDG-PET for end-of-therapy response assessment in p-NHL may not be 
considered favorable. From the results, the likelihood ratio was calculated as 1.75. By 
contrast, in p-HL, Furth et al. examined 40 patients and they reported that the sensitivity, 
specificity, PPV, NPV, and accuracy of the end-therapy response assessment were 100%, 
78%, 25%, 100%, and 79%, respectively, with the likelihood ratio of 4.5.
10
 They concluded 
15 
 
that in response assessment of p-HL patients, those with a negative PET result would have 
an excellent prognosis, while those with a positive result would have an increased risk for 
relapse. As compared with their results for p-HL, the present study of p-NHL showed a 
lower likelihood ratio. The sensitivity and NPV were lower in our population. Relapse of 
disease occurred even in the PET-negative cases. Mody et al. studied 26 patients with p-
NHL for end-of-therapy response assessment and reported that among four patients with a 
negative PET result, there were two patients who relapsed within 12 months.
20 
The present 
data suggest that the role of FDG-PET for end-of-therapy response assessment may be 
limited, and negative PET results may not necessarily imply a favorable outcome in p-NHL, 
unlike those in p-HL where several studies have demonstrated the utility of such a finding. 
The International Harmonization Project provided updated guidelines on the use of PET 





however, in pediatric cases, NHL could have different characteristics and distinct 
histological subtypes from NHL in adults.
3
 
For routine surveillance after complete remission, FDG-PET is currently not 
recommended.
3
 In p-HL, Levine et al. and Meany et al. found that PET was sensitive but 
not specific for post-treatment evaluation with a strong NPV (100%) but poor PPV (11–
18%).
21, 22
 In the present study for surveillance of p-NHL, we also found a low PPV (33%). 
Several benign conditions such as post-therapeutic inflammation or physiological activities 
are liable to cause false-positive results in pediatric patients. FDG accumulation into 
rebound thymic hyperplasia is common among children and adolescents.
 
The accumulation 
into activated brown adipose tissue can often be observed unless the room temperature is 
16 
 
moderately warmed. Conversely, in the present study PET was of value in identifying 
relapse in two patients, and showed excellent sensitivity. Therefore, although the role of 
FDG-PET for surveillance in asymptomatic people remains unsettled, we believe it may 
provide beneficial information if there are clinical signs of relapse. 
Our results suggest several features that distinguish p-NHL from p-HL and from 
lymphoma in adults. Therefore, we believe the role of FDG PET should also differ. Several 
drawbacks due to the more aggressive behaviors of p-NHL may reduce the utility of PET 
for disease staging and response assessment. Several benign conditions that are 
characteristic in children could also hinder the diagnostic performance of PET. The role of 
FDG-PET in staging for determining more appropriate therapeutic strategy may be 
somewhat different between p-HL and p-NHL.
12
 In p-HL, more detailed and accurate 
information regarding the spread of involved lesions is required to plan the delivery of 
radiotherapy, and FDG-PET often provides information resulting in correct up-staging.
23
 
Conversely, in p-NHL where treatment is typically risk-adapted intensive chemotherapy 
without radiotherapy, the precise localization of every site of small bulk disease is not 
always necessary to achieve high cure rates.
24
 Moreover, for stage IV patients already 
diagnosed by bone marrow biopsy or cerebrospinal fluid cytology, FDG-PET can no longer 
contribute to either up-staging or the alteration of treatment strategy. For response 
assessment or surveillance of relapse, we believe the difference of biological behavior, 
especially the difference of the aggressiveness between p-HL and p-NHL, would explain 
our suggestion that FDG might have a more limited role for p-NHL than for p-HL. As 







 cells and the limit of resolution of FDG-PET for the detection of 




 cells. FDG-PET can only measure 
the first 2-3 log units of tumor cell killing, depending on the initial size of tumor.
25
 In short, 
a negative PET result does not indicate total eradication of disease. Most of p-NHL would 
have higher aggressiveness than p-HL, and we presume that in p-NHL even a small amount 
of tumor cells below the level of the detectability of PET would overcome anti-tumor 
immunity. However, we emphasize the ability of PET to identify unexpected lesions, which 
may occur more frequently in p-NHL, even during therapy. The use of PET could be quite 
effective in some lesions, such as involvement of peripheral nerves or focal bone marrow 
involvement that cannot be easily identified by other imaging modalities. 
There exists a trade-off between repeated PET scans, especially PET/CT scans, and 
lifetime risk of cancer incidence attributable to increasing radiation dose. Many pediatric 
patients with malignancy tend to undergo repeated scans. Therefore, the reasonable use of 
the scans is required to avoid unnecessary radiation exposure. Modifying imaging protocols 
so as to minimize injected FDG activity and CT dose according to patients’ size is required. 
The present study has several limitations. It was not prospective and thus our population 
might contain a bias. Also, the size of the study population was not large. The follow-up 
periods varied among the patients and the protocols used for image acquisition and injected 
dose were not unified because PET studies were performed with three different scanners. 
In conclusion, FDG-PET for p-NHL can sometimes contribute to the determination of 
more appropriate therapeutic strategies by identifying unexpected lesions; however, its 
clinical role may not be as promising when compared with the developing consensus about 
18 
 
p-HL. Clinicians should make every effort to perform PET/CT scanning properly so as to 
reasonably reduce the lifetime risk of secondary cancers in pediatric patients. Because p-
NHL has considerably distinct clinical characteristics from p-HL, prospective 
investigations regarding p-NHL cases might be needed to establish the optimal role of 
FDG-PET. 
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Fig. 1 Patients’ grouping 
 
Fig. 2 Concordance and discordance between CIM and PET judgments about the 
achievement of remission in Group B 
 
Fig. 3 A 3-year-old boy (No. 2) with Burkitt lymphoma with peripheral nerve involvement. 
The cerebrospinal cytology was positive at the initial staging. At the end of chemotherapy, 
he complained of a nocturnal crural pain. FDG-PET showed lymphoma involvement in the 
sciatic nerves (straight arrows) in addition to a known abdominal tumor (wavy arrow). He 
was scheduled to undergo surgical resection of the remnant abdominal tumor if the 
chemotherapy was effective, but it was cancelled as a result of progressive disease (A: 
Maximum intensity projection image, B: fused PET/CT image) 
 
Fig. 4 An 11-year-old boy (No. 9) with T-lymphoblastic lymphoma of thymus. He was 
regarded as having achieved complete response. The scan for response assessment (A) only 
showed physiological thymic uptake. However, eight months later, he underwent FDG-PET 
again for surveillance (B) and was found to have relapse in the thymus. Focal intense 
uptake superimposed on the physiological uptake (arrow) was identified.  The tumor was 
resected and relapse was confirmed 






Table 1 Patient profile 






































5 9 M Lymphoblastic IV A 1 CR 
6 5 M Lymphoblastic IV A 1 CR 
7 3 M Burkitt IV B 1 CR 










death after CR 
10 5 M Burkitt IV B 1 CR 










13 14 F Burkitt III→IV† B 16 Relapse 





15 18 F DLBCL I C 1 CR 
16 15 M Lymphoblastic I C 1 CR 
17 18 M Burkitt II C 2 CR 
18 17 M DLBCL IV C 5 CR 
19 8 M DLBCL II C 6 CR 
Abbreviations: Pt. #, Patient number; PET, positron emission tomography; M, male; F, female; ALCL, 
anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; NK-T, Natural killer-T cell; N.A., 
not available; CR, complete remission. 
* Although the clinical stage was considered stage III by PET, cerebrospinal fluid cytology turned out to be 
positive. 
†Although the initial staging was stage III, bone marrow involvement occurred as a relapse after therapy and 
so was classified as stage IV at re-staging. 
 
Table 2 Summary of stages and findings in CIM and PET, and final diagnoses in Group A 
Pt. 
# 
Histology CIM  PET Final diagnoses 
1 Lymphobl
astic 
Stage IV: No residual lesion 
after excision of CNS tumor 
with skull involvement 
Stage IV: the same as CIM Stage IV: CNS involvement 
(surgically proven) 
2 Burkitt Stage III: Extensive and 
unresectable intra-abdominal 
mass, abdominal lymph 
nodes swelling, and ascites 
Stage III: Extensive primary 
intra-abdominal mass and 
abdominal lymph nodes with 
intense uptake 
Stage IV: Positive 
cerebrospinal fluid cytology 
3 ALCL Stage II: Multiple 
subcutaneous nodules in legs 
Stage II: Multiple 
subcutaneous nodules with 
high uptake in legs 
Stage II: Greater numbers of 
small papules visually 
identified in legs and back 
(biopsy-proven) 
4 DLBCL Stage III: Multiple intra-
abdominal extra-nodal 
masses, internal thoracic 
nodes swelling, and pleural 
effusion 
Stage III: Multiple abdominal 
masses, some of which 
existed along the peritoneum. 
Internal thoracic nodes and 
subcarinal nodes also showed 
high uptake 
Stage III:  DLBCL was 
proved by internal thoracic 
node biopsy, but stage was 
determined by radiological 




Stage III: Huge anterior 
mediastinal mass with 
invasion to thyroid, 
pericardium, and lung 
Stage III: Huge anterior 
mediastinal mass with intense 
uptake. Diffuse moderate 
bone marrow uptake as an 
inconclusive finding 




Stage IV: Huge destructive 
bone tumor of scapula 
Stage IV: Intense uptake into 
scapular tumor 
 Stage IV: (Biopsy-proven) 
Abbreviations: CIM, conventional imaging modalities; CNS, central nerve system 
Table 3 Comparison of CIM staging vs. PET staging vs. reference standard in Group A 
(n=6) CIM diagnosis PET diagnosis Final diagnosis 
Stage I 0 0 0 
II 1 1 1 
III 3 3 1 
IV 2* 2* 4 
* One patient with CNS involvement was diagnosed by excision, as their disease stage was already known as 
stage IV before undergoing PET and CT scanning. 
 Table 4 Summary of cases in Group B in which FDG-PET influenced the treatment plan 
Pt.# Status CIM findings PET findings Influence on treatment plan 
2 End-CTx response 
assessment 
+: The abdominal 
tumor grew despite 
chemotherapy. 
+: Sciatic nerve 
involvement was 
identified in addition to 
the known abdominal 
lesion. 
Withdrawal of the standard 
chemotherapy / Cancellation 
of the planned surgical 
resection of the remnant 
abdominal tumor. (The 
involvement was confirmed 
by cerebrospinal fluid 
cytology.)  
13 Salvage CTx response 
assessment for relapse 
of the distal femur  
-: No residual lesion 
was identified on CT. 
+: Relapse of scapula 
was identified.  
Withdrawal of the standard 
chemotherapy / Only 
rituximab was continued as 
palliative therapy. (The 




13 Salvage CTx response 
assessment for relapse 
of  scapula 
-: No residual lesion 
was identified on CT. 
+: Re-relapse of 
scapula after remission 
was identified. 
RTx for scapula / 




13 Salvage CTx & RTx 
response assessment 
Not performed +: Relapse of ilium was 
identified, while the 
RTx for the ilium. (No 
histological confirmation) 
for relapse of scapula uptake in the scapula 
disappeared. 
Abbreviations: CTx, chemotherapy; RTx, radiotherapy; +, positive results; -, negative results. 
Table 5 Diagnostic performances at completion of remission-induction chemotherapy for 
predicting relapse (Subgroup B+) 
(n=11) CIM PET 
Positive Negative Positive Negative 
No. of relapse 2 2 2 2 
No. of remission 2 5 2 5 
Sensitivity 50% 50% 
Specificity 71% 71% 
PPV 50% 50% 
NPV 71% 71% 
Accuracy 64% 64% 
Abbreviations: PPV, Positive predictive value; NPV, Negative predictive value. 
The two results were not identical. In one case, CIM showed false-positive but PET showed true-negative. In 
another one case, CIM showed true-negative but PET showed false-positive. 
 
Table 6 Diagnostic performance of PET for detection of relapse after achievement of 




 Positive Negative 
Final diagnosis No. of relapsed cases 2 0 
 No. of non-relapsed cases 4 26 
Sensitivity 100% 
Specificity 87% 
PPV 33% 
NPV 100% 
Accuracy 88% 
 
